The Valley Desk

ArticleRegulatory toxicology and pharmacology : RTPPublished

FIH dose selection beyond MABEL: Optimizing phase 1 clinical trial starting dose whilst protecting patient safety

Read the publication ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Regulatory toxicology and pharmacology : RTP
Published
Subject terms
Animals; Humans; Immunologic Factors; Risk Assessment; Dose-Response Relationship, Drug; Models, Biological; Clinical Trials, Phase I as Topic; Patient Safety; Drug Development; Immunomodulating Agents
PubMed ID
41621794
Added to directory
Source checked

Report a correction or request removal